Stock listing
LSE:POLB Poolbeg Pharma PLC Share Price
Home listing (LSE) of Poolbeg Pharma PLC
Follow Poolbeg Pharma PLC into a list and get an email when it puts out news.
Share price · LSE:POLB
6.15p GBX (pence) -0.25 (-3.9%)
Close on Nov 20, 2026
- Day range
- 6.10p – 6.30p GBX (pence)Nov 20, 2026
- Volume
- 998,803 sharesNov 20, 2026
- Market cap
- £46.95M GBPAt the close on Nov 20, 2026 · price × 763.4M shares outstanding
- 52-week range
- 3.30p – 9.30p GBX (pence)Lowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- £132,845 GBPMedian day 1.03M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| LSE:POLB · Home | 6.15p GBX (pence) | -0.25 (-3.9%) | 998,803 | 6.20p | 6.30p | 6.10p | 6.40p | Close on Nov 20, 2026 |
| Frankfurt:7JN | €0.063 EUR | +0.002 (+3.3%) | — | €0.063 | €0.063 | €0.063 | €0.061 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · LSE:POLB · GBX (pence), adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 6.15p | -0.25 | -3.9% | 6.20p | 6.30p | 6.10p | 998,803 | |
| 6.40p | -0.05 | -0.8% | 6.45p | 6.50p | 6.275p | 731,243 | |
| 6.45p | +0.35 | +5.7% | 6.10p | 6.50p | 5.90p | 1,646,207 | |
| 6.10p | +0.25 | +4.3% | 5.85p | 6.30p | 5.80p | 1,033,488 | |
| 5.85p | 0.00 | 0.0% | 5.85p | 6.00p | 5.70p | 98,345 | |
| 5.85p | 0.00 | 0.0% | 5.85p | 6.00p | 5.75p | 403,210 | |
| 5.85p | +0.05 | +0.9% | 5.80p | 6.00p | 5.73p | 221,855 | |
| 5.80p | -0.20 | -3.3% | 6.00p | 6.00p | 5.70p | 732,626 | |
| 6.00p | -0.05 | -0.8% | 6.05p | 6.05p | 5.90p | 325,787 | |
| 6.05p | +0.05 | +0.8% | 6.10p | 6.20p | 6.00p | 346,435 | |
| 6.00p | -0.40 | -6.3% | 6.30p | 6.30p | 6.00p | 1,102,742 | |
| 6.40p | 0.00 | 0.0% | 6.40p | 6.45p | 6.30p | 185,026 | |
| 6.40p | 0.00 | 0.0% | 6.40p | 6.50p | 6.30p | 215,082 | |
| 6.40p | -0.10 | -1.5% | 6.50p | 6.70p | 6.30p | 415,295 | |
| 6.50p | 0.00 | 0.0% | 6.50p | 6.60p | 6.30p | 403,346 | |
| 6.50p | -0.15 | -2.3% | 6.65p | 6.695p | 6.332p | 304,561 | |
| 6.65p | 0.00 | 0.0% | 6.65p | 6.697p | 6.50p | 460,013 | |
| 6.65p | -0.10 | -1.5% | 6.75p | 6.897p | 6.60p | 778,385 | |
| 6.75p | +0.09 | +1.4% | 6.45p | 6.897p | 6.335p | 1,528,062 | |
| 6.66p | +0.16 | +2.5% | 6.50p | 6.66p | 6.315p | 287,905 | |
| 6.50p | +0.25 | +4.0% | 6.25p | 6.70p | 6.10p | 1,865,446 | |
| 6.25p | 0.00 | 0.0% | 6.25p | 6.40p | 5.894p | 2,248,702 | |
| 6.25p | 0.00 | 0.0% | 6.25p | 6.40p | 6.10p | 584,172 | |
| 6.25p | -0.05 | -0.8% | 6.30p | 6.50p | 6.10p | 247,094 | |
| 6.30p | -0.30 | -4.5% | 6.40p | 6.50p | 6.10p | 929,307 | |
| 6.60p | +0.20 | +3.1% | 6.35p | 6.60p | 6.20p | 643,308 | |
| 6.40p | -0.10 | -1.5% | 6.50p | 6.60p | 6.30p | 1,580,972 | |
| 6.50p | -0.40 | -5.8% | 6.90p | 6.90p | 6.30p | 2,972,319 | |
| 6.90p | 0.00 | 0.0% | 6.90p | 7.00p | 6.80p | 412,852 | |
| 6.90p | 0.00 | 0.0% | 6.90p | 7.00p | 6.833p | 583,157 | |
| 6.90p | 0.00 | 0.0% | 6.90p | 7.00p | 6.80p | 489,113 | |
| 6.90p | -0.30 | -4.2% | 7.15p | 7.21p | 6.80p | 3,245,625 | |
| 7.20p | +0.20 | +2.9% | 7.10p | 7.30p | 6.90p | 831,462 | |
| 7.00p | -0.18 | -2.5% | 7.10p | 7.30p | 6.90p | 594,920 | |
| 7.18p | -0.17 | -2.3% | 7.35p | 7.50p | 6.90p | 1,127,024 | |
| 7.35p | -0.05 | -0.7% | 7.35p | 7.50p | 7.20p | 1,029,441 | |
| 7.40p | 0.00 | 0.0% | 7.35p | 7.50p | 7.20p | 554,887 | |
| 7.40p | +0.05 | +0.7% | 7.35p | 7.50p | 7.20p | 545,125 | |
| 7.35p | +0.25 | +3.5% | 7.10p | 7.60p | 7.052p | 6,680,306 | |
| 7.10p | -0.80 | -10.1% | 7.85p | 8.00p | 6.56p | 15,336,310 | |
| 7.90p | -1.15 | -12.7% | 9.15p | 9.30p | 7.50p | 10,213,737 | |
| 9.05p | +0.05 | +0.6% | 9.00p | 9.30p | 8.80p | 1,511,750 | |
| 9.00p | 0.00 | 0.0% | 9.00p | 9.20p | 8.802p | 647,637 | |
| 9.00p | +0.15 | +1.7% | 8.85p | 9.20p | 8.70p | 2,766,692 | |
| 8.85p | -0.20 | -2.2% | 9.05p | 9.30p | 8.70p | 528,905 | |
| 9.05p | +0.10 | +1.1% | 8.95p | 9.30p | 8.80p | 1,241,303 | |
| 8.95p | +0.25 | +2.9% | 8.70p | 9.14p | 8.60p | 2,953,490 | |
| 8.70p | +0.30 | +3.6% | 8.40p | 8.80p | 8.30p | 720,027 | |
| 8.40p | +0.10 | +1.2% | 8.35p | 8.50p | 8.30p | 849,412 | |
| 8.30p | -0.10 | -1.2% | 8.40p | 8.55p | 8.30p | 2,518,226 | |
| 8.40p | +0.05 | +0.6% | 8.35p | 8.50p | 8.30p | 1,298,629 | |
| 8.35p | -0.05 | -0.6% | 8.40p | 8.50p | 8.30p | 331,576 | |
| 8.40p | +0.10 | +1.2% | 8.35p | 8.50p | 8.30p | 1,684,536 | |
| 8.30p | +0.05 | +0.6% | 8.25p | 8.44p | 8.20p | 1,407,519 | |
| 8.25p | -0.33 | -3.8% | 8.40p | 8.50p | 8.20p | 1,473,549 | |
| 8.58p | +0.34 | +4.1% | 8.25p | 8.58p | 8.20p | 4,492,676 | |
| 8.24p | -0.11 | -1.3% | 8.35p | 8.50p | 8.20p | 1,126,084 | |
| 8.35p | -0.25 | -2.9% | 8.45p | 8.80p | 8.30p | 2,166,547 | |
| 8.60p | +0.20 | +2.4% | 8.45p | 8.60p | 8.30p | 2,290,227 | |
| 8.40p | -0.20 | -2.3% | 8.65p | 9.00p | 8.40p | 3,210,258 | |
| 8.60p | 0.00 | 0.0% | 8.60p | 8.80p | 8.40p | 1,816,142 | |
| 8.60p | +0.10 | +1.2% | 8.50p | 9.00p | 8.40p | 4,910,295 | |
| 8.50p | -0.30 | -3.4% | 8.80p | 9.00p | 8.40p | 3,090,204 | |
| 8.80p | -0.20 | -2.2% | 8.95p | 9.20p | 8.70p | 1,909,752 | |
| 9.00p | +0.35 | +4.0% | 8.65p | 9.20p | 8.50p | 2,656,061 |
- Ticker
- LSE:POLB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- LSE
- Currency
- GBX
What changed lately
Latest news release · Oct 6, 2026
POLB001 CRS Patent Granted in South Korea
Latest earnings call · Sep 24, 2026
Poolbeg Pharma (LSE:POLB) — Company Presentation
Replay and transcript
Latest deck · Oct 28, 2026
Investor Presentation (October 2026)
Investor deck · 24 slides
Latest news
POLB001 CRS Patent Granted in South Korea
Oct 6, 2026
Closed 7.20p (+2.9%) on Oct 6, 2026
Interim Results for the six months to 30 June 2026
Sep 29, 2026
Closed 7.40p (+0.7%) on Sep 29, 2026
POLB 001 TOPICAL trial recruitment update
Sep 28, 2026
Closed 7.35p (+3.5%) on Sep 28, 2026
Interim data from POLB 001 TOPICAL clinical trial
Sep 24, 2026
Closed 7.90p (-12.7%) on Sep 24, 2026
Key Conference Participation in September 2026
Sep 3, 2026
Closed 8.58p (+4.1%) on Sep 3, 2026
Notification of major holdings
Jul 23, 2026
Closed 6.15p (+0.8%) on Jul 23, 2026
Notice of Allowance for POLB 001 patent in Israel
Jul 21, 2026
Closed 6.20p (+0.6%) on Jul 21, 2026
Placing to raise £3.5 million
Jul 14, 2026
Closed 6.05p (-13.6%) on Jul 14, 2026
First patient dosed in POLB 001 TOPICAL trial
Jul 13, 2026
Closed 7.00p (0.0%) on Jul 13, 2026
POLB 001 patent granted in South Africa
Jun 30, 2026
Closed 6.85p (+1.5%) on Jun 30, 2026
Poolbeg Pharma PLC on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 25 in the last 12 months · 144 in all · newest Oct 6, 2026 · oldest 2021
- Calls
- 12 calls with a replay · 12 with a transcript · latest Sep 24, 2026
- Decks
- 16 decks · latest Oct 28, 2026
Where Poolbeg Pharma PLC is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| LSE:POLB · Home listing · This page | LSE | United Kingdom | GBX |
| OTC:POLBF | OTC | United States | USD |
| Frankfurt:7JN | Frankfurt | Germany | EUR |
| Stuttgart:7JN | Stuttgart | Germany | EUR |
Valuation
Price/book 7.0× against a median of 2.9×: 7th lowest of 11 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- £42.13M GBP
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 7.0×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Poolbeg Pharma PLC · LSE:POLB | US$61.42M | US$55.12M | n/a | n/a | n/a | 7.0× | n/a | 0.0× | n/a |
| AlzeCure Pharma AB · OMXSTO:ALZCUR | US$63.84M | US$62.72M | 21.3× | 6.6× | 25.6× | 7.1× | 31.6% | 0.0× | n/a |
| Lytix Biopharma ASA · OSL:LYTIX | US$63.10M | US$53.73M | n/a | n/a | n/a | 7.1× | n/a | 0.0× | n/a |
| Neumora Therapeutics, Inc. · NASDAQ:NMRA | US$63.01M | US$30.65M | n/a | 1,916× | n/a | 3.4× | n/a | 2.9× | 1.07 |
| ViGenCell, Inc. · KRX:308080 | US$61.45M | US$44.89M | n/a | 65.1× | n/a | 2.1× | n/a | 0.2× | n/a |
| vTv Therapeutics Inc. · NASDAQ:VTVT | US$61.33M | −US$15.84M | n/a | −0.4× | n/a | 0.9× | −20.8% | 0.0× | 1.28 |
| Oncopeptides AB · OMXSTO:ONCO | US$61.17M | US$58.97M | n/a | 6.3× | n/a | 25.1× | −223.6% | 5.4× | n/a |
| HemoGenyx Pharmaceuticals PLC · LSE:HEMO | US$60.45M | US$56.88M | n/a | n/a | n/a | 10.7× | n/a | 0.4× | n/a |
| Genexine, Inc. · KRX:095700 | US$60.38M | US$44.48M | n/a | 12.0× | n/a | 0.4× | −650.0% | 0.0× | n/a |
| ISU Abxis Co., Ltd. · KRX:086890 | US$60.20M | US$42.54M | n/a | 1.1× | n/a | 0.7× | −16.0% | 0.0× | n/a |
| GlycoNex, Inc. · TPEX:4168 | US$59.92M | US$57.20M | n/a | 84.9× | n/a | 2.3× | n/a | 0.6× | n/a |
| Median of the others | US$61.25M | US$49.31M | 21.3× | 9.3× | 25.6× | 2.9× | −20.8% | 0.1× | 1.18 |
Forecasts
Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 19.00 GBX · Analysts' mean
- EPS, year to Dec 2026
- -0.007 · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jeremy Skillington | Chief Executive Officer |
| Ian O’Connell | Chief Financial Officer |
| Carol Dalton | VP, Investor Relations & Public Relations |
| Bruno Speder | VP of Regulatory Affairs |
| Meena Arora | VP, Medical Affairs & Development |
| Cathal Friel | Executive Chair |
Board
| Director | Role |
|---|---|
| Cathal Friel | Executive Chair |
| Brendan Buckley | Non Executive Director |
| Eddie Gibson | Non-Executive Director |
| Luke O’Neill | Non-Executive Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Poolbeg Pharma (LSE:POLB) — Company Presentation | Thu, Sep 24, 2026 · 9:00 AM ET | Replay |
| Poolbeg Pharma (LSE:POLB) Q4 2025 Earnings Call | Tue, Apr 28, 2026 · 12:00 PM ET | Replay |
| Poolbeg Pharma (LSE:POLB) — POLB 001 Phase 2a Trial Update | Mon, Sep 29, 2025 · 12:00 PM ET | Replay |
| Poolbeg Pharma (LSE:POLB) — Company Presentation | Mon, Jun 23, 2025 · 12:00 PM ET | Replay |
| Poolbeg Pharma (LSE:POLB) — Investor Presentation | Wed, Feb 26, 2025 · 12:00 PM ET | Replay |
| Poolbeg Pharma (LSE:POLB) — Company Presentation | Tue, Apr 30, 2024 · 1:00 PM ET | Replay |
| Poolbeg Pharma (LSE:POLB) — POLB 001 Update | Wed, Jan 17, 2024 · 1:00 PM ET | Replay |
| Poolbeg Pharma (LSE:POLB) — Company Update | Fri, Nov 10, 2023 · 7:30 AM ET | Replay |
| Poolbeg Pharma (LSE:POLB) — Full Year Results | Thu, Mar 30, 2023 · 5:00 AM ET | Replay |
| Poolbeg Pharma (LSE:POLB) — Investor Presentation | Wed, Dec 14, 2022 · 12:30 PM ET | Replay |
All 12 calls
| Call | When | Status |
|---|---|---|
| Poolbeg Pharma (LSE:POLB) — Interim Results | Tue, Sep 06, 2022 · 1:00 PM ET | Replay |
| Poolbeg Pharma (LSE:POLB) — Investor Presentation | Thu, Mar 03, 2022 · 1:00 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q4 2025 | Feb 26, 2026 | −4.3% |
| Q2 2025 | Sep 29, 2025 | −7.7% |
| Quarter to Mar 31, 2025 | May 27, 2025 | +53.1% |
| Q1 2023 | Apr 12, 2023 | −2.4% |
| Q2 2022 | Sep 6, 2022 | +5.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 24 slides | Oct 28, 2026 |
| Investor Presentation (October 2026) | Investor deck | 38 slides | October 2026 |
| Q4 2025 Earnings Presentation | Earnings | 35 slides | Apr 28, 2026 |
| Investor Presentation (June 2025) | Investor deck | 34 slides | June 2025 |
| Investor Presentation (May 2025) | Investor deck | 32 slides | May 2025 |
| Investor Presentation (May 2025) | Investor deck | 29 slides | May 2025 |
| Investor Presentation (May 2024) | Investor deck | 38 slides | May 2024 |
| Investor Presentation (July 2023) | Investor deck | 28 slides | July 2023 |
| Investor Presentation (January 2023) | Investor deck | 46 slides | January 2023 |
| Investor Presentation (February 2022) | Investor deck | 26 slides | February 2022 |
All 16 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2022) | Investor deck | 25 slides | January 2022 |
| Investor Presentation (December 2021) | Investor deck | 21 slides | December 2021 |
| Investor Presentation (November 2021) | Investor deck | 21 slides | November 2021 |
| Investor Presentation (October 2021) | Investor deck | 22 slides | October 2021 |
| Investor Presentation (October 2021) | Investor deck | 22 slides | October 2021 |
| Investor Presentation (July 2021) | Investor deck | 21 slides | July 2021 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of new ordinary shares Closed: £3.5M raised · GBX 6 a share · OAK Securities Dealers: OAK Securities (lead) Buyers: Cathal Friel (£250,000 subscription) Insiders: Executive Chair Cathal Friel subscribed a further £250,000 Use of proceeds: Fund the POLB 001 TOPICAL trial and the oral GLP-1 proof-of-concept trial to completion; strengthen partnering position | Sep 29, 2026 | US$4.63M |
| Private placement of new ordinary shares Made bigger: £4.87M · GBX 2.5 a share · Shore Capital +1 Dealers: Shore Capital (lead), Shore Capital Stockbrokers Limited (lead) Buyers: Cathal Friel (4,000,000 new Ordinary Shares, investment of £100,000) Insiders: Executive Chair Cathal Friel subscribed for 4,000,000 new Ordinary Shares, an investment of £100,000 Use of proceeds: Phase 2a trial of POLB 001 for cancer immunotherapy-induced CRS, oral GLP-1 proof-of-concept trial, cash runway into 2027 | Jun 23, 2025 | US$6.56M |
| BookBuild Offer Shares (new ordinary shares) Made bigger: £150,000 · GBX 2.5 a share · Shore Capital +1 Dealers: Shore Capital (lead), Shore Capital Stockbrokers Limited Use of proceeds: Fund POLB 001 Phase 2a trial and oral GLP-1 proof of concept trial, providing runway into 2027 | May 22, 2025 | US$201,316 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in GBP
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 59.0K | 114.0K | 26.0K | 26.0K | 18.0K |
| Gross profit | -59.0K | -114.0K | -26.0K | -26.0K | -18.0K |
| Research and development | 1.52M | 1.38M | 1.68M | 2.20M | 414.0K |
| Selling, general and administrative | 4.89M | 5.26M | 3.38M | 3.06M | 2.03M |
| Operating income | -6.42M | -6.62M | -5.04M | -4.99M | -2.38M |
| Depreciation and amortization | 59.0K | 114.0K | 26.0K | 26.0K | 18.0K |
| EBITDA | -6.36M | -6.50M | -5.01M | -4.96M | -2.36M |
| Interest expense | 0 | ||||
| Income before tax | -5.77M | -5.94M | -4.50M | -4.78M | -2.34M |
| Income tax | -79.0K | 154.0K | -574.0K | -91.0K | 42.0K |
| Net income | -5.70M | -5.79M | -3.93M | -4.69M | -2.34M |
| Earnings per share, basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.00 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | 7.71M | 7.82M | 12.2M | 16.2M | 20.9M |
| Receivables | 364.0K | 519.0K | 700.0K | 962.0K | 8.00K |
| Inventory | -1.33M | -962 | 0 | ||
| Current assets | 8.27M | 8.56M | 13.5M | 17.2M | 21.5M |
| Total assets | 9.94M | 10.2M | 15.4M | 19.3M | 23.0M |
| Accounts payable | 151.0K | 165.0K | 79.0K | 293.0K | 79.0K |
| Current liabilities | 1.34M | 974.0K | 986.0K | 966.0K | 438.0K |
| Total liabilities | 1.34M | 974.0K | 986.0K | 966.0K | 438.0K |
| Shareholders' equity | 8.60M | 9.27M | 14.4M | 18.3M | 22.6M |
| Shares outstanding | 602.7M | 500.0M | 497.6M | 500.0M | 500.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash from operations | -4.51M | -4.65M | -4.38M | -4.37M | -2.15M |
| Capital spending | -4.51M | -129.0K | -175.0K | -597.0K | -81.0K |
| Free cash flow | -4.84M | -4.78M | -4.02M | -4.96M | -2.23M |
| Cash from investing | -80.0K | 299.0K | 359.0K | -388.0K | -81.0K |
| Cash from financing | 4.48M | 23.2M | |||
| Change in cash | -111.0K | -4.35M | -4.02M | -4.76M | 20.9M |
Cap table
Built by 6ix from Poolbeg Pharma PLC’s releases · as of Sep 29, 2026
- Common shares
- 763,437,106
- Fully diluted
- 763,437,106
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 763,437,106 | Sep 29, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Sep 29, 2026 | 763,437,106 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Cathal Friel Other companies: European Green Transition PLC (Co-Founder & Executive Chair · Since at least Apr 14, 2025) | Executive Chair · Since at least Sep 29, 2026 |
| Brendan Buckley | Non Executive Director · Since at least May 13, 2026 |
| Bruno Speder | VP of Regulatory Affairs · Since at least May 26, 2026 |
| Carol Dalton | VP, Investor Relations & Public Relations · Since at least Nov 4, 2026 |
| Eddie Gibson | Non-Executive Director · Since at least Nov 4, 2026 |
| Ian O’Connell | Chief Financial Officer · Since at least Oct 6, 2026 |
| Jeremy Skillington | Chief Executive Officer · Since at least Oct 6, 2026 |
| Luke O’Neill | Non-Executive Director · Since at least Mar 12, 2026 |
| Meena Arora | VP, Medical Affairs & Development · Since at least May 13, 2026 |
Log in to ask 6ix AI your own questions about Poolbeg Pharma PLC.